Bhuvana Ramkumar, MD

Articles

The Future of Molecular Testing in NSCLC

November 9th 2022

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Financial Considerations with Molecular Testing for Patients With NSCLC

November 9th 2022

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Receiving Molecular Testing Results for NSCLC

November 2nd 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Integrating Molecular Testing Results into Electronic Medical Records

November 2nd 2022

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Using Liquid Biopsy for Molecular Testing in NSCLC

October 26th 2022

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

October 26th 2022

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Average Turnaround Time for NSCLC Molecular Testing

October 19th 2022

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Best Practices for Accurate Tissue Genotyping in NSCLC

October 19th 2022

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Enhancing Communication Among the Multidisciplinary Care Team

October 12th 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Challenges With and Strategies for Tissue Procurement in NSCLC

October 12th 2022

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.